Startling Study: Teen Cannabis Use Linked to 11x Higher Psychosis Risk

A study shows teenagers using cannabis may be 11 times more likely to develop a psychotic disorder than non-users. This relationship seems particularly strong during adolescence, highlighting the increased potency of cannabis as a significant factor. Credit: SciTechDaily.com

Research links teen cannabis use to a significantly higher risk of psychotic disorders, emphasizing the impact of increased THC potency.

A new study published today (May 22) in the journal Psychological Medicine estimates that teens using cannabis are at an 11 times higher risk of developing a psychotic disorder compared to teens not using cannabis.

This finding suggests that the association between cannabis and psychotic disorders may be stronger than indicated by previous research, which has relied largely on older data when cannabis was less potent than today. For context, the average THC potency of cannabis in Canada has increased from roughly 1% in 1980 to 20% in 2018.

Researchers from the University of Toronto, the Centre for Addiction and Mental Health (CAMH), and ICES, linked recent population-based survey data from over 11,000 youth in Ontario, Canada, to health service use records including hospitalizations, emergency department (ED) visits, and outpatient visits.

The study is the first to show an age-dependent association between self-reported cannabis use and subsequent psychotic disorder diagnosis, which adds to a growing body of research on the mental health risks associated with cannabis.

A new study shows that teens using cannabis are at 11 times higher risk of developing a psychotic disorder compared to teens not using cannabis. Credit: ICES

Insights From the Lead Researcher

“We found a very strong association between cannabis use and risk of psychotic disorder in adolescence. Surprisingly, we didn’t find evidence of association in young adulthood,” says lead author André McDonald, who conducted the study at ICES as part of his PhD at the University of Toronto. McDonald is now a postdoctoral fellow at the Peter Boris Centre for Addictions Research and the Michael G. DeGroote Centre for Medicinal Cannabis Research at McMaster University. “These findings are consistent with the neurodevelopmental theory that teens are especially vulnerable to the effects of cannabis.”

Of the teens who were hospitalized or visited an ED for a psychotic disorder, roughly 5 in 6 had previously reported cannabis use. McDonald points out that, “the vast majority of teens who use cannabis will not develop a psychotic disorder, but according to these data, most teens who are diagnosed with a psychotic disorder likely have a history of cannabis use.”

Limitations and Implications

The researchers could not completely rule out reverse causation, in that teens with psychotic symptoms may have been self-medicating with cannabis before receiving a clinical diagnosis. They also could not account for potentially important factors such as genetics and history of trauma. These limitations make it impossible to say definitively that teen cannabis use causes psychotic disorders. The authors also note that their estimates are only approximate, suggesting that further studies with larger samples are required.

Concerns and Preventive Measures

Despite these limitations, the findings add to worries about early cannabis use, particularly in the wake of legalization.

“As commercialized cannabis products have become more widely available, and have a higher THC content, the development of prevention strategies targeting teens is more important than ever,” says senior author Susan Bondy, an affiliate scientist at ICES and associate professor at the University of Toronto’s Dalla Lana School of Public Health.

McDonald adds, “Canadian youth are among the heaviest users of cannabis in the world. If we follow the precautionary principle, the bottom line is that more needs to be done to prevent early cannabis use.”

Reference: “Age-dependent association of cannabis use with risk of psychotic disorder” by André J. McDonald, Paul Kurdyak, Jürgen Rehm, Michael Roerecke and Susan J. Bondy, 22 May 2024, Psychological Medicine.
DOI: 10.1017/S0033291724000990